Five-Year Review of HIV-Hepatitis B Virus (HBV) Co-Infected Patients in a New York City AIDS Center

• DOI: 10.3346/jkms.2012.27.7.830
• Publication Date: 2012-07-06T06:48:26Z
• Authors: Jong Hun Kim; George Psevdos; Victoria Sharp
• Keywords: Adult; Liver Cirrhosis; Male; Anti-HIV Agents; Coinfection; Adenine; Organophosphonates; HIV Infections; Middle Aged; Brief Communication; Hepatitis B; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Humans; Female; New York City; Hepatitis B e Antigens; Tenofovir; Retrospective Studies

A retrospective review of 4,721 human immunodeficiency virus (HIV)-infected patients, followed at St. Luke's Roosevelt Hospital Center, New York City, was conducted from January 1, 2005 to December 31, 2009. HIV-Hepatitis B virus (HBV) co-infection rate was 218/4,721, 4.6%. Among co-infected patients, 19 patients (19/218, 8.7%) died; 13 patients (13/19, 68.4%) died from non-acquired immune deficiency syndrome (AIDS) defining including 2 patients with liver failure. More non-survivors (5 patients, 5/19, 26.3%) had liver cirrhosis than those who survived (8 patients, 8/199, 4.0%; P = 0.002). There were more patients with positive HBV e antigen (HBeAg) among non-survivors, (12 patients, 12/19, 63.2%) than among survivors (74 patients, 74/199, 37.2%; P = 0.047). HIV-HBV co-infection is associated with increased overall mortality. Therefore, use of dual active antiretrovirals, particularly, tenofovir (TDF) based regimen for optimal suppression of HIV-HBV and immune restoration with prevention of high risk behaviors may contribute to improved outcomes.